Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.

Abstract

The COVID-19 pandemic spurred the rapid development of a range of therapeutic antibody treatments. As part of the US government's COVID-19 therapeutic response, a research team was assembled to support assay and animal model development to assess activity for therapeutics candidates against SARS-CoV-2. Candidate treatments included monoclonal antibodies, antibody cocktails, and products derived from blood donated by convalescent patients. Sixteen candidate antibody products were obtained directly from manufacturers and evaluated for neutralization activity against the WA-01 isolate of SARS-CoV-2. Products were further tested in the Syrian hamster model using prophylactic (-24 h) or therapeutic (+8 h) treatment approaches relative to intranasal SARS-CoV-2 exposure. In vivo assessments included daily clinical scores and body weights. Viral RNA and viable virus titers were quantified in serum and lung tissue with histopathology performed at 3d and 7d post-virus-exposure. Sham-treated, virus-exposed hamsters showed consistent clinical signs with concomitant weight loss and had detectable viral RNA and viable virus in lung tissue. Histopathologically, interstitial pneumonia with consolidation was present. Therapeutic efficacy was identified in treated hamsters by the absence or diminution of clinical scores, body weight loss, viral loads, and improved semiquantitative lung histopathology scores. This work serves as a model for the rapid, systematic in vitro and in vivo assessment of the efficacy of candidate therapeutics at various stages of clinical development. These efforts provided preclinical efficacy data for therapeutic candidates. Furthermore, these studies were invaluable for the phenotypic characterization of SARS CoV-2 disease in hamsters and of utility to the broader scientific community.

• Authors: Yu Cong, Eric M Mucker, Donna L Perry, Saurabh Dixit, Erin Kollins, Russ Byrum, Louis Huzella, Robert Kim, Mathew Josleyn, Steven Kwilas, Christopher Stefan, Charles J Shoemaker, Jeff Koehler, Susan Coyne, Korey Delp, Janie Liang, David Drawbaugh, Amanda Hischak, Randy Hart, Elena Postnikova, Nick Vaughan, Jason Asher, Marisa St Claire, Jarod Hanson, Connie Schmaljohn, Ann E Eakin, Jay W Hooper, Michael R Holbrook
• Journal: Antiviral research (Antiviral Res) Vol. 213 Pg. 105589 (05 2023) ISSN: 1872-9096 [Electronic] Netherlands
• PMID: 37003305 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Published by Elsevier B.V.

Chemical References

• Antibodies, Monoclonal
• RNA, Viral

Topics

• Cricetinae
• Animals
• Humans
• SARS-CoV-2
• Mesocricetus
• COVID-19
• Pandemics
• Antibodies, Monoclonal (therapeutic use)
• Disease Models, Animal
• RNA, Viral